Evaluating the Effect of Taladafil on the Treatment of Severe Asthma

The Effect of Taladafil on Improvement of Lung Function and Asthma Attacks in Patients with Severe Asthma

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200823048482N1

Enrollment

Registered

2020-09-09

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma. Asthma

Interventions

Intervention 1: Intervention group: This Group Received a Single 50 mg Dose of Oral Taladafil (Made in Ahvaz Pharmacy faculty) Daily During One Month. Intervention 2: Control group: This Group Receive

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The Patients with Severe Asthma

Exclusion criteria

Exclusion criteria: Mild to moderate severity Using Immunosuppressive Drug and Corticosteroid ( Greater than 5 mg Dose) Outside the Study Protocol in Three Months Ago Advanced Liver Failure (Liver Cirrhosis), Advanced Renal Failure (CKD Stage 4,5) Pregnancy Uncontrolled Hypertension Havingany Untreated Disease such as Reflux, Sinusitis or Allergic Bronchopulmonary Aspergillosis (ABPA) based on History and Paraclinical Tests which Trigger Asthma Exacerbation Continuously Prohibition of Phosphodiesterase Inhibitors and Nitrate Consumption

Design outcomes

Primary

Measure	Time frame
Lung Volume (Forced expiratory volume in one second); (FEV1). Timepoint: In the First Referral and One Month Later. Method of measurement: Spirometry Test.;Lung Volume (Forced Vital Capacity); (FVC). Timepoint: In the First Referral and One Month Later. Method of measurement: Spirometry Test.;Lung Volume (Forced Expiratory flow 25_75%); (FEF25-75%). Timepoint: In the First Referral and One Month Later. Method of measurement: Spirometry Test.;Forced Expiratory Volume in 1 Second to Forced Vital Capacity (FEV1/FVC). Timepoint: In the First Referral and One Month Later. Method of measurement: Spirometry Test.;Quality of Life Score (Upon Quality of Life Questionnaire in Asthmatic Patients). Timepoint: In the First Referral and One Month Later. Method of measurement: Questionnaire.	—

Measure

Time frame

Lung Volume (Forced expiratory volume in one second); (FEV1). Timepoint: In the First Referral and One Month Later. Method of measurement: Spirometry Test.;Lung Volume (Forced Vital Capacity); (FVC). Timepoint: In the First Referral and One Month Later. Method of measurement: Spirometry Test.;Lung Volume (Forced Expiratory flow 25_75%); (FEF25-75%). Timepoint: In the First Referral and One Month Later. Method of measurement: Spirometry Test.;Forced Expiratory Volume in 1 Second to Forced Vital Capacity (FEV1/FVC). Timepoint: In the First Referral and One Month Later. Method of measurement: Spirometry Test.;Quality of Life Score (Upon Quality of Life Questionnaire in Asthmatic Patients). Timepoint: In the First Referral and One Month Later. Method of measurement: Questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed Hamid Borsi

Ahvaz University of Medical Sciences

borsi-h@ajums.ac.ir+98 61 3221 5574

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026